Global Market Study on Immune Checkpoint Inhibitors: North America’s Dominance in the Market will Remain Unchallenged during 2017 - 2026

Immune Checkpoint Inhibitors  Market
  • Published On : Nov-2017 |
  • Pages : 170 Pages |
  • Format :

Persistence Market Research (PMR) has published a yet another exclusive forecast analysis on the global immune checkpoint inhibitors market. The report, titled “Immune Checkpoint Inhibitors Market – Global Industry Analysis (2012-2016) and Forecast (2017-2026)”, examines key aspects impacting expansion of the global Immune checkpoint inhibitors market, and offers in-depth insights on the market for the forecast period, 2017-2026. The report delivers information on latest trends influencing expansion of the market in the next ten years. Competitive landscape of the global Immune checkpoint inhibitors market has been explored extensively in the report, deriving baseline values regarding market size estimations by aggregating revenues of market players.

Report Structure

The report starts with a chapter on executive summary of global Immune checkpoint inhibitors market, which highlights key research findings, especially across drug class and regional segments. A snapshot of the market size estimations, along with the forecast evaluations has been provided in this chapter. The report also offers an overview of the market, including standard definition of “Immune checkpoint inhibitors” coupled with a brief introduction of the market on the basis of analytical assessment.

The report offers market size estimations & forecast in terms of key metrics including compounded annual growth rate, year-on-year growth rate, basis point share index, and absolute dollar opportunity. Moving further, the report studies dynamic expansion of the global Immune checkpoint inhibitors market. This chapter provides analysis on factors restraining or driving the worldwide adoption of Immune checkpoint inhibitors. Lucrative opportunities and key trends are compiled in this chapter for enabling market players in considering the untapped entities for expansion of their business in the immediate future.

Market Taxonomy

Key chapters in this report deliver segmentation analysis on the global Immune checkpoint inhibitors market. The market numbers concerning the segmentation analysis are offered in terms of the market share comparison, year-on-year growth comparison, and revenue comparison. On the basis of regions, the global Immune checkpoint inhibitors market is divided into Latin America, North America, Middle East & Africa (MEA), Japan, Asia-Pacific excluding Japan (APEJ), and Europe. Country-specific forecasts and cross-segmental analysis are also been provided in these chapters. The table given below represents the taxonomy employed for studying future of the global Immune checkpoint inhibitors market.


Drug Class

Distribution Channel

Therapeutic Application

  • North America
  • PD-1
  • Hospital Pharmacies
  • Melanoma
  • Latin America
  • PD-L1
  • Retail Pharmacies
  • Lung Cancer
  • Europe
  • CTLA-4
  • Specialty Pharmacies
  • Blood Cancers
  • Japan
  • Renal Cell Carcinoma
  • APEJ
  • Squamous Cell Carcinoma
  • MEA
  • Urothelial Carcinoma
  • Colorectal Cancer
  • Other Cancers

Competition Landscape

Last chapters in the report offer knowledge about global immune checkpoint inhibitors market’s competition landscape. In these chapters, the report delivers Information pertaining to the market players in terms of product overview, SWOT analysis, key developments, company overview, and key financials of the market players. Chapters on the market’s competition landscape are considered to be an indispensable part of the report, which provide readers with access to a detailed knowledge base to help them understand the past and current standings of prominent industries that actively contribute to global immune checkpoint inhibitors market’s expansion. These chapters of the report offer essential information about the way of players’ strategy implementation through which they aim in increasing their global market presence.

Research Methodology

Analysts at PMR have developed a comprehensive research methodology to come up with credible insights on future of various markets. Immune checkpoint inhibitors is more likely an emerging development in treatment of cancers, and is witnessing applications in the global healthcare marketplace. For developing this report, accuracy of these forecast market evaluations are assured by infusing the qualitative information with the quantitative data. Inferences delivered in this report may enable developers of Immune checkpoint inhibitors for devising informed strategies. A wide range of primary as well as secondary research methodologies have been employed for developing these inferences. Opinions of key industry leaders are assessed for validating viewpoints of PMR’s analysts. By availing this report, companies can easily take informed decisions regarding future market direction.

Immune checkpoint inhibitors are drugs or drug candidates, which block/inhibit the inhibitory checkpoint molecules, often referred to as checkpoint blockade. Immune checkpoint inhibitors are used for treatment of various types of cancers including melanoma, lung cancer, blood cancer, renal cell carcinoma, squamous cell carcinoma, urothelial carcinoma, and colorectal cancer.

Immune Checkpoint Inhibitors are Successful in Treating Patients with Metastatic Cancer

Immune checkpoint inhibitors have been hailed by oncologists as one of the major breakthroughs for treatment of cancer, with impressive long-lasting and durable responses. Cancer-affected patients have been provided with extended years of life following treatment with immune checkpoint inhibitors. These drugs have been deemed quite successful in treating patients with metastatic cancer, especially lung cancer and melanoma. Here, these drugs have transformed the once referred as fatal diseases into chronic conditions. Immune checkpoint inhibitors are considered to have immense potential in treating renal cell carcinoma, and urothelial cancer.

The U.S. Food and Drug Administration (FDA) has recently approved five immune checkpoint inhibitor drugs viz. ipilimumab (Yervoy®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), avelumab (Bavencio®), and atezolizumab (Tecentriq®). In addition, various clinical trials on immune checkpoint inhibitor drugs for a wide range of conditions are being carried out by leading drug manufacturers. A major issue witnessed in employing immune checkpoint inhibitors is their effectiveness for only a few types of cancers, owing to the cancer cells’ property of inhibiting pathways affecting T cell functions. Scientists are therefore commencing to address the issue through different drug combinations, and developing treatment methods that target immune-evasion mechanisms.


The global immune checkpoint inhibitors market is projected to ride on a high double-digit CAGR during the forecast period (2017-2026), according to a new research study by Persistence Market Research (PMR). Revenues from the market are estimated to exceed US$ 30,000 Mn by 2026-end.

PD-1 Inhibitors to Remain Sought-after among Drug Class in the Market

On the basis of drug class, PD-1 inhibitors are expected to remain sought-after in the market, with sales poised to exceed US$ 20,000 Mn by 2026-end. PD-1 inhibitors have replaced the existing radiotherapy and chemotherapy procedures for cancer therapeutics. In addition, numerous clinical trials are being carried out for combination therapy regarding PD-1 inhibitors across the globe. Revenue share of PD-1 inhibitors will remain considerably larger than all the other drug class available in the market during the forecast period.

Immune checkpoint inhibitors will continue to witness the largest therapeutic application in lung cancer, followed by melanoma. Revenues from these two therapeutic applications of immune checkpoint inhibitors are projected to account for over half share of the market in 2017. Demand for immune checkpoint inhibitors in treating lung cancer will register a significant decline, while demand in treating melanoma will gain a slight uptick by 2026-end.

Specialty Pharmacies to be Fastest Expanding Distribution Channel for Immune Checkpoint Inhibitors

Specialty pharmacies are projected to be the fastest expanding distribution channel for immune checkpoint inhibitors during the forecast period, however revenues from specialty pharmacies will remain relatively lower than all the other distribution channels in the market. Retail pharmacies are expected to account for a comparatively larger revenue share of the market than specialty pharmacies by 2026-end.

Dominance of North America in the global immune checkpoint inhibitors market is anticipated to remain unchallenged. The region is projected to account for over two-third share of the market during 2017 to 2026, in terms of revenues. The market in Europe will register a comparatively higher CAGR than that in North America, to become the second most lucrative market for immune checkpoint inhibitors by 2026-end.

Competition Tracking

Key companies profiled by PMR in its report include AstraZeneca, Bristol-Myers Squibb, Celldex Therapeutics, F. Hoffman-La Roche, Incyte Corporation, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Mirada Medical Limited, Sciencesoft USA Corporation, Siemens Healthineers, Toshiba Medical Systems Corporation, and Xinapse Systems Ltd.

Company Profile

  • AstraZeneca Plc.      
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • Roche Holding AG
  • Incyte Corporation
  • Merck & Co., Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Others.
Back To Top